Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay)
(Note: Up to 8-plex in one testing reaction)
- Product No.LMA831Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypePlasma
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.39-400pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.13 pg/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 349
US$ 363
US$ 383
US$ 410
US$ 437
US$ 477
US$ 538
Result
For more details, please contact local distributors! US$ 672 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 89-96 | 93 |
EDTA plasma(n=5) | 83-102 | 88 |
heparin plasma(n=5) | 98-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 93-103% | 83-97% | 94-104% | 95-102% |
EDTA plasma(n=5) | 78-101% | 79-94% | 83-101% | 86-103% |
heparin plasma(n=5) | 78-104% | 82-102% | 90-98% | 99-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:TAT) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
IUBMB LIFE | Genetic repression of mouse VEGF expression regulates coagulation cascade. PubMed: 21086498 |
Thrombosis Research | Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice ScienceDirect: S0049384811004166 |
Journal of Thrombosis and Haemostasis | High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality Wiley: source |
3 | Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling Nature: 20120329 |
Am J Respir Cell Mol Bio | Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury PubMed: PMC2993087 |
PLoS One | Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa Sepsis PubMed: PMC3521733 |
Haemetology | Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India Pubmed: 23992124 |
Am J Transl Res. | Selected hemostatic parameters in patients with pancreatic tumors. Pubmed:Pmc4297344 |
PLOS ONE | TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like Response Pubmed:24489651 |
Leukemia | Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs) Pubmed:24667943 |
Anesthesia & Analgesia | Thrombomodulin Improved Liver Injury, Coagulopathy, and Mortality in an Experimental Heatstroke Model in Mice Pubmed:24781566 |
Cell Transplantation | Evidence of a Pivotal Role for the Distal Part of the Complement Cascade in the Diurnal Release of Hematopoietic Stem Cells Into Peripheral Blood Pubmed:26087465 |
European Journal of Pharmacology | (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coaCavia (Guinea pig )lation Pubmed:27343380 |
J Thromb Haemost. | Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis. pubmed:27813324 |
Blood Cells, Inflammation and Infection | Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury pubmed:29202212 |
SCIENCE TRANSLATIONAL MEDICINE | Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension pubmed:28148841 |
32 | Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target pubmed:28289017 |
Thrombosis andHaemostasis | Nebulized anti-coagulants as a therapy for acute lung injury and acute respiratory distress syndrome Pubmed: 29202212 |
Thrombosis Research | The circadian rhythm of selected parameters of the hemostasis system in healthy people |
Experimental Neurobiology | Transduced Tat-aldose Reductase Protects Hippocampal Neuronal Cells against Oxidative Stress-induced Damage Pubmed: 31698553 |
LIVER TRANSPLANTATION | The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia‐reperfusion injury in mice Pubmed: 33108682 |
Am J Physiol Heart Circ Physiol | Doxorubicin contributes to thrombus formation and vascular injury via enhancing platelet functions in vivo Pubmed: 32469636 |
Intensive Care Medicine Experimental | Preservation of renal endothelial integrity and reduction of renal edema by aprotinin does not preserve renal perfusion and function following experimental … 34169407 |
Intensive Care Med Exp | Complement factor D is linked to platelet activation in human and rodent sepsis 34396466 |